STZ Model – The streptozotocin-induced rat/mouse diabetes model
A Powerful Tool for Diabetic Nephropathy Preclinical Research and Drug Testing.
Diabetic Nephropathy, a common complication of diabetes, presents significant challenges in treatment and management. Our meticulously designed STZ rat/mouse model offers researchers a reliable platform to explore the intricate mechanisms underlying this pathological condition including renal fibrosis, inflammation and glomerular alterations.
Why Choose Our Streptozotocin (STZ) Rat/Mouse Model?
- Reflects Human Pathophysiology: Our model accurately mimics the progression of diabetic nephropathy seen in humans, providing researchers with a faithful representation of the disease’s complexities.
- Versatile and Reliable: Whether you’re exploring disease progression, evaluating novel therapeutic interventions, or screening potential drug candidates, our rat model offers versatility and reliability in experimental outcomes.
- Highly Reproducible Results: Our STZ rat model delivers reproducible results, enabling confident data interpretation and robust scientific conclusions.
- Ethical and Compliant: We adhere to the highest ethical standards and regulatory guidelines in animal research, ensuring the welfare and well-being of our animal subjects at every stage.
Partner with us to advance your research goals and accelerate the development of innovative therapies with our validated STZ Rat/Mouse Model.
Usually rats but validated also in mice with multiple low dose injections
From 8 to 12 weeks allowing a longitudinal evaluation of therapeutic compounds
Multiple parametric analyses, including histopathology, biochemistry, and gene expression studies
Study design STZ rat model
Assay readouts
